

# Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

Yoon K. Loke MBBS MD, Sonal Singh MD MPH, Curt D. Furberg MD PhD

Published at www.cmaj.ca on Dec. 10, 2008.

∞ See related commentary by Lipscombe, page 16

## ABSTRACT

**Background:** Rosiglitazone and pioglitazone may increase the incidence of fractures. We aimed to determine systematically the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect of the therapy on bone density.

**Methods:** We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), other trial registries and product information sheets through June 2008. We selected long-term ( $\geq 1$  year) randomized controlled trials involving patients with type 2 diabetes and controlled observational studies that described the risk of fractures or changes in bone density with thiazolidinediones. We calculated pooled odds ratios (ORs) for fractures and the weighted mean difference in bone density.

**Results:** We analyzed data from 10 randomized controlled trials involving 13 715 participants and from 2 observational studies involving 31 679 participants. Rosiglitazone and pioglitazone were associated with a significantly increased risk of fractures overall in the 10 randomized controlled trials (OR 1.45, 95% confidence interval [CI] 1.18–1.79;  $p < 0.001$ ). Five randomized controlled trials showed a significantly increased risk of fractures among women (OR 2.23, 95% CI 1.65–3.01;  $p < 0.001$ ) but not among men (OR 1.00, 95% CI 0.73–1.39;  $p = 0.98$ ). The 2 observational studies demonstrated an increased risk of fractures associated with rosiglitazone and pioglitazone. Bone mineral density in women exposed to thiazolidinediones was significantly reduced at the lumbar spine (weighted mean difference  $-1.11\%$ , 95% CI  $-2.08\%$  to  $-0.14\%$ ;  $p = 0.02$ ) and hip (weighted mean difference  $-1.24\%$ , 95% CI  $-2.34\%$  to  $-0.67\%$ ;  $p < 0.001$ ) in 2 randomized controlled trials.

**Interpretation:** Long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes.

Une version française de ce résumé est disponible à l'adresse [www.cmaj.ca/cgi/content/full/180/1/32/DC1](http://www.cmaj.ca/cgi/content/full/180/1/32/DC1)

CMAJ 2009;180(1):32-9

and Progression Trial (ADOPT).<sup>6</sup> The manufacturers of rosiglitazone<sup>7</sup> and pioglitazone followed this up by issuing warning letters about the risk of fractures.<sup>7-9</sup>

Women with type 2 diabetes are at an increased risk of non-vertebral fractures,<sup>10</sup> with a near doubling in the risk of hip fractures.<sup>11</sup> Any additional risk from thiazolidinedione therapy could have a considerable impact. Our primary objective was to determine systematically the relative and absolute risks of fractures with long-term thiazolidinedione therapy for type 2 diabetes. We also reviewed the effect of thiazolidinedione therapy on bone mineral density to ascertain its biological plausibility.

## Methods

### Search strategy

We searched MEDLINE, EMBASE and the Cochrane Central Registry of Controlled Trials (CENTRAL) through June 2008. We also searched the websites of regulatory authorities, manufacturers' product information sheets, and the registers of clinical trials of GlaxoSmithKline,<sup>12</sup> Takeda Pharmaceuticals,<sup>13</sup> and the Clinical Study Results database<sup>14</sup> for unpublished studies. We checked existing systematic reviews and the bibliographies of the studies that were included. Finally, we used the Web of Science Citation Index to identify relevant articles of high impact. Our search strategy is outlined in Appendix 1 (available at [www.cmaj.ca/cgi/content/full/180/1/32/DC2](http://www.cmaj.ca/cgi/content/full/180/1/32/DC2)).

### Eligibility criteria

We selected randomized controlled trials and controlled observational studies that compared the risk of fracture among patients with type 2 diabetes who were taking thiazolidinedione therapy and patients not taking this therapy.

We included randomized controlled trials that met the following inclusion criteria: parallel-design trial of any thiazolidinedione (rosiglitazone, pioglitazone or troglitazone) of at least one year's duration. The participants had impaired glucose tolerance or type 2 diabetes mellitus; each study used either placebo or oral therapy with an active comparator as the control arm; the treatment groups differed only in the use of

Recent systematic reviews have focused on the adverse cardiovascular effects of the thiazolidinediones rosiglitazone and pioglitazone.<sup>1-5</sup> In late 2006, the risk of fractures with the use of rosiglitazone was raised in a footnote of the report of the A Diabetes Outcome

From the School of Medicine, Health Policy and Practice (Loke), University of East Anglia, Norwich, UK; and the Section on General Internal Medicine, Department of Medicine (Singh), and the Division of Public Health Sciences (Furberg), Wake Forest University School of Medicine, Winston-Salem, USA

thiazolidinediones; and the studies reported clearly on fracture outcomes.

For the secondary outcome of effects of thiazolidinediones on bone mineral density, we selected randomized controlled trials and controlled observational studies of any duration that compared changes in bone mineral density in patients with and without thiazolidinedione exposure.

### Validity assessment

We assessed the reporting of allocation concealment and the use of blinding in the randomized controlled trials. In accordance with the Cochrane handbook for systematic reviews of interventions, we assessed the strength of data on adverse effects in both the randomized controlled trials and the observational studies by noting how the investigators monitored and recorded adverse effects.<sup>15</sup>

### Data abstraction

Two reviewers (Y.K.L and S.S.), both independently and as a team, assessed the eligibility and quality of studies for reporting of adverse events. They extracted numerical data on outcomes from the studies included in our analysis. The reviewers achieved consensus on inclusion of the studies and data extraction. Any discrepancies were resolved through discussion. They also contacted authors about items that required clarification.

### Study characteristics

From the randomized controlled trials, we recorded the dose and duration of thiazolidinedione therapy and the baseline characteristics of the participants. From the observational studies, we recorded information on the sources of data, the participants, the verification of exposure and the outcomes.

### Data synthesis

We used fixed-effects models to calculate pooled odds ratios (ORs), with 95% confidence intervals (CIs), for dichotomous outcomes. We calculated weighted mean differences for continuous outcomes. The fixed-effects Mantel-Haenszel model is the appropriate method for meta-analysis of rare events.<sup>16</sup> All reported *p* values are 2-sided, with significance set at *p* less than 0.05. Statistical heterogeneity was assessed using the *I*<sup>2</sup> statistic, with 95% CIs.<sup>17,18</sup> A substantial level of heterogeneity is indicated by *I*<sup>2</sup> values of 50% or more.<sup>17</sup>

We also carried out a predefined sensitivity analysis to determine the influence of trial duration and statistical models on effect size. We estimated the fail-safe number using the Rosenberg method to assess the potential impact of missing data in the meta-analysis (i.e., the number of additional negative trials that would be required to reverse a significant finding in the meta-analysis).<sup>19</sup>

We calculated the number needed to harm by applying the pooled OR from the

meta-analysis to the control event rate in different populations.<sup>20,21</sup> The number needed to harm is the number of patients with type 2 diabetes who must be treated with a thiazolidinedione (rather than another intervention) for 1 additional patient to have a fracture. To account for variation in follow-up, we calculated the number needed to harm using person-years as denominators.<sup>22</sup>


## Results

The selection of trials is summarized in Figure 1. Overall, 10 randomized controlled trials involving a total of 13 715 participants reported on fractures.<sup>23–32</sup> All of the trials were double-blinded. We judged allocation concealment to be adequate in 6 trials<sup>23,24,27,30,32</sup> and unclear in 4 trials.<sup>26,28,29,31</sup> All of the trials included participants with impaired glucose tolerance<sup>31</sup> and type 2 diabetes.<sup>23–30,32</sup> The duration was from 1 to 4 years.<sup>23</sup> Data on fractures were available by sex in 5 trials.<sup>23,24,30,32</sup> The participants in the treatment groups were similar to the control patients with respect to ethnic background, disease duration, glycosylated hemoglobin and body mass index in these 5 trials. Full descriptions of the characteristics of the 10 trials are shown in Appendix 2 (available at [www.cmaj.ca/cgi/content/full/180/1/32/DC2](http://www.cmaj.ca/cgi/content/full/180/1/32/DC2)).

### Risk of fractures

Figure 2 shows the pooled data from the 10 randomized controlled trials evaluating the risk of fractures associated with thiazolidinediones overall, and by sex.

We found that thiazolidinediones significantly increased the risk of overall fractures compared with controls (OR 1.45, 95% CI 1.18–1.79; *p* < 0.001); the statistical heterogeneity was moderate (*I*<sup>2</sup> = 27%) (Figure 2A).



**Figure 1:** Selection of randomized controlled trials of thiazolidinedione use for meta-analysis of risk of fractures in patients with type 2 diabetes mellitus.

The pooled data from the 5 trials that reported fracture risk by sex (4400 women, 7001 men) showed that thiazolidinediones significantly increased the risk of fractures among women compared with controls (OR 2.23, 95% CI 1.65–3.01;  $p < 0.001$ ) (Figure 2B); there was no statistical heterogeneity among the included trials ( $I^2 = 0\%$ ). Thiazolidinediones did not significantly increase the risk of fractures among men (OR 1.00, 95% CI 0.73–1.39;  $p = 0.98$ ;  $I^2 = 0\%$ ) (Figure 2C). Statistical testing for interaction confirmed a significant difference between the male and female subgroups ( $\chi^2 12.01$ ,  $p < 0.001$ ).

The characteristics of the 2 observational studies that reported on the association between thiazolidinedione exposure and fractures are shown in Appendix 3 (available at [www.cmaj.ca/cgi/content/full/180/1/32/DC2](http://www.cmaj.ca/cgi/content/full/180/1/32/DC2)).<sup>33,34</sup> The case-control study by Meier and colleagues<sup>33</sup> showed a significant association between thiazolidinedione exposure (current users with  $> 8$  prescriptions) and fractures among women (OR 2.56, 95% CI 1.43–4.58). In the cohort study, rosiglitazone was significantly associated with fractures when compared with women taking metformin (OR 1.38, 95% CI 1.03–1.82), but no signif-




Figure 2: Meta-analysis of fractures in randomized controlled trials of thiazolidinedione versus control.

icant elevation of fracture risk was seen in the comparison of rosiglitazone and sulfonylurea (OR 0.89, 95% CI 0.69–1.14).<sup>34</sup> No significant association between thiazolidinedione exposure and fractures among men was found in either study.

### Sensitivity analyses

The sensitivity analysis using a random-effects model yielded estimates similar to those of the fixed-effects model for the risk of fractures associated with thiazolidinediones among women (OR 2.19, 95% CI 1.62–2.97;  $p < 0.001$ ). Overall fractures (OR 1.32, 95% CI 0.91–1.92) and fractures among men (OR 1.00, 95% CI 0.73–1.39) were not statistically significant in the sensitivity analysis.

The sensitivity analysis based on the 6 longer-term randomized controlled trials (18 months to 4 years)<sup>23,24,30–32</sup> showed an elevated risk of fracture (OR 1.51, 95% CI 1.18–1.79;  $p < 0.001$ ). The sensitivity analysis of the 4 smaller trials of 12 months' duration<sup>26–29</sup> showed a nonsignificant risk of fracture (OR 0.41, 95% CI 0.12–1.44;  $p = 0.16$ ).

Similarly, the association with fractures in the case–control study became apparent among patients who received more than 8 thiazolidinedione prescriptions (corresponding to about 12–18 months of therapy).<sup>33</sup> The cohort study enrolled 27 000 patients with 30 600 patient-years of follow-up, which indicated that, on average, participants were exposed for just over a year.<sup>34</sup> With this relatively short duration of exposure, the OR for the rosiglitazone–metformin comparison was elevated only moderately at 1.38, and no significant association was seen in the rosiglitazone–sulfonylurea comparison.

To reverse the significantly increased risk of fractures among women shown in our meta-analysis, we estimated that 42 negative studies with an average sample size of 880 women each would be required.<sup>19</sup>

### Change in bone mineral density

We identified 2 relevant randomized controlled trials<sup>35,36</sup> and 2 observational studies<sup>37,38</sup> (Table 1). All 4 studies showed a consistent decline in bone mineral density associated with thiazolidinediones compared with controls.

The meta-analysis of the percentage point change in bone mineral density in both trials among women who used thia-

**Table 1:** Studies showing the effects of thiazolidinediones on bone mineral density

Study	Design	Population	Treatment groups (no. of patients)	Outcome measures	% of change in bone mineral density, mean (SD)*			
					Hip		Lumbar spine	
					Thiazolidinedione	Control	Thiazolidinedione	Control
Grey et al. <sup>35</sup>	14-week double-blind RCT; adequate allocation concealment	50 healthy postmenopausal women in the community; mean age 68 years	<ul style="list-style-type: none"> <li>Rosiglitazone (25)</li> <li>Placebo (25)</li> </ul>	Dual energy radiographic absorptiometry of proximal femur and lumbar spine; biochemical measure of bone resorption	-1.2 (SD 2.1)	-0.2 (SD 2.1)	-1.9 (SD 2.0)	-0.2 (SD 1.6)
Glintborg et al. <sup>36</sup>	16-week double-blind RCT; allocation concealment unclear	44 premenopausal women with polycystic ovary syndrome; mean age 32 years	<ul style="list-style-type: none"> <li>Pioglitazone (30)</li> <li>Placebo (14)</li> </ul>	Dual energy radiographic absorptiometry of bone mineral density; biochemical measure of bone metabolism	-1.02 (SD 2.66)	0.34 (SD 2.78)	-0.41 (SD 2.03)	0.67 (SD 2.46)
Yaturu et al. <sup>37</sup>	Retrospective controlled cohort study; mean follow-up 16 months	160 men with type 2 diabetes with similar baseline measurements of bone mineral density; mean age 69 years	<ul style="list-style-type: none"> <li>Rosiglitazone (32)</li> <li>Control (128)</li> </ul>	Annualized percentage of change in bone mineral density using dual-energy radiographic absorptiometry	0.69 (SD 2.4)	2.3 (SD 2.9)	-1.19 (SD 1.8)	-0.14 (SD 1.9)
Schwartz et al. <sup>38</sup>	4-year prospective cohort study in Health ABC Study	666 older diabetic adults in the community, with and without self-reported thiazolidinedione use; age range 70–79 years	<ul style="list-style-type: none"> <li>Troglitazone (22)</li> <li>Pioglitazone (30)</li> <li>Rosiglitazone (31)</li> </ul>	Annualized percentage of change in bone mineral density using dual-energy radiographic absorptiometry, done every 2 years	Women: -1.23 (95% CI -2.06 to -0.40) additional change per year of drug use Men: -0.25 (95% CI -1.10 to 0.60) additional change per year of drug use		Women: -0.49 (95% CI -1.04 to 0.07) additional change per year of drug use Men: -0.19 (95% CI -0.61 to 0.22) additional change per year of drug use	

Note: CI = confidence interval, RCT = randomized controlled trial, SD = standard deviation.  
\*Unless stated otherwise.

thiazolidinediones showed a significant reduction at the lumbar spine (weighted mean difference  $-1.11\%$ , 95% CI  $-2.08\%$  to  $-0.14\%$ ;  $p = 0.02$ ;  $I^2 = 0\%$ ) and at the hip (weighted mean difference  $-1.24\%$  (95% CI  $-2.34\%$  to  $-0.67\%$ ;  $p < 0.001$ ;  $I^2 = 0\%$ ).<sup>35,36</sup> Adding the observational data from the study by Yaturu and colleagues<sup>37</sup> yielded similar findings at the lumbar spine (weighted mean difference  $-1.36\%$ , 95% CI  $-2.05\%$  to  $-0.67\%$ ;  $p = 0.001$ ;  $I^2 = 0\%$ ) and at the hip (weighted mean difference  $-1.24\%$ , 95% CI  $-1.78\%$  to  $-0.70\%$ ;  $p < 0.001$ ;  $I^2 = 0\%$ ) compared with controls (Figure 3).

We excluded 1 observational study from the meta-analysis because its outcome data were reported in a different format.<sup>38</sup>

### Estimated number needed to harm

The relative risk of fractures with thiazolidinediones remained consistently elevated irrespective of age<sup>33</sup> or menopausal status of women.<sup>23</sup> Therefore, we used the single pooled relative risk to estimate the number needed to harm across different age groups.<sup>39</sup> Table 2 shows the variation in the number needed to harm and the number of excess fractures with different baseline populations. The patient populations ranged from patients

with newly diagnosed type 2 diabetes at low risk of fractures who were in the metformin arm of the ADOPT study (number needed to harm 55, 95% CI 34–103)<sup>23</sup> to older postmenopausal women with type 2 diabetes at high risk of fracture (number needed to harm 21, 95% CI 14–39).<sup>40</sup>

### Interpretation

Our meta-analysis showed that the long-term use of thiazolidinediones doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes. Overall, use of thiazolidinediones significantly increased the risk of fractures among patients with type 2 diabetes. Thiazolidinedione exposure was also associated with significant changes in bone mineral density at the lumbar spine and the hip.

A posthoc analysis of fracture risk with rosiglitazone in the ADOPT study failed to show any clear relation to ethnicity, hypoglycemia, weight gain or age.<sup>23</sup> However, thiazolidinediones may cause fractures by increasing adiposity of bone marrow, decreasing osteoblast activity or reducing aromatase activity,




Figure 3: Change in bone mineral density in trials and observational studies.

each of which alters estrogen production and increases bone resorption.<sup>38</sup> Thiazolidinediones have a negative effect on markers of bone formation such as alkaline phosphatase and parathyroid hormone.<sup>35,36,41</sup> In rodent models, rosiglitazone was found to decrease osteoblastic function, which led to bone loss.<sup>42–44</sup> Thiazolidinediones may also promote osteoclast differentiation and bone resorption.<sup>45</sup> No proven strategies exist for reducing the risk of fractures induced by thiazolidinediones. Elderly postmenopausal women with type 2 diabetes may not be protected by bisphosphonate therapy.<sup>46</sup>

The underlying mechanism for the apparent sex-specific effect of thiazolidinediones needs further investigation. In animal studies, bone loss occurred with rosiglitazone treatment in rats that had their ovaries removed, but not in rats that were intact.<sup>47</sup> This indicated that higher levels of sex steroids may protect against fractures in men.<sup>48</sup>

The predominance of fractures in the upper and distal lower limbs with thiazolidinedione therapy, with the relative paucity of hip fractures in the trials, may be attributed to the age of the participants (the mean age was 56 years in the ADOPT study<sup>23</sup>). In the observational study by Sanders and colleagues,<sup>49</sup> the most commonly found fractures in people 55–64 years of age were in the distal upper and lower limbs, whereas the majority (92%) of hip fractures occurred in women over 75 years. The low baseline incidence of hip fractures in the trials' relatively young participants means that the trials lacked the power to detect any significant increase in hip fracture risk (Appendix 4, available at [www.cmaj.ca/cgi/content/full/180/1/32/DC2](http://www.cmaj.ca/cgi/content/full/180/1/32/DC2)). However, the case-control study involving an older female population (60% were over 60 years) showed that fractures of the hip and femur were significantly associated with thiazolidinedione therapy (OR 4.54, 95% CI 1.28–16.10).<sup>33</sup>

The public health impact may be considerable. There were more than 4 million individual users of thiazolidinediones in the United States in 2006.<sup>50</sup> If one assumes that half of those users were women and that the baseline risk of fractures is similar to that found in the ADOPT study,<sup>23</sup> an estimated

30 000 excess fractures may have occurred if these women had been prescribed thiazolidinediones rather than metformin for more than a year. The excess number of fractures with thiazolidinediones would be 3-fold higher if they experienced fractures at the rates found in population studies<sup>10,40</sup> rather than at the conservative levels of baseline risk levels of the trials. There is no clear evidence that other oral hypoglycemic agents such as metformin and the sulfonylureas are associated with an increased risk of fractures.<sup>51</sup> Previous observational studies have suggested an increased risk of fracture associated with insulin use, likely due to confounding by severity and duration of diabetes and the presence of comorbidities.<sup>52,53</sup>

Our results highlight the failure of pharmacovigilance mechanisms that rely on follow-up of spontaneous reports.<sup>54</sup> We found only a handful of reports of fracture with thiazolidinedione use in the databases of the US Food and Drug Administration in 2006 and Health Canada in 2006.<sup>55,56</sup> However, in 2001, Quesada-Gomez and Serrano-Alferez<sup>57</sup> had already called for randomized trials to “examine changes in bone mass and risk for fractures.” Moreover, Rzonca and colleagues<sup>43</sup> had warned in 2004 that “rosiglitazone therapy may pose a significant risk of adverse skeletal effects in humans.”

### Limitations

Our meta-analysis has several limitations, which are mainly due to the paucity of reported data. None of the trials we included was prospectively designed to measure the risk of fractures. Nevertheless, incidence rates of fractures in the control arms of the trials were consistent with those found in large-scale epidemiologic studies.<sup>49</sup> We did not have sufficient data to determine whether the risk varied with the particular drug or with different fracture sites. Our estimates of the number needed to harm are valid only for women receiving more than 12 months of thiazolidinedione therapy within the context of specific populations.

We excluded 17 long-term trials of at least 12 months' duration from our analysis because they did not report fracture rates. Although they are unlikely to reverse the direction or

**Table 2:** Number needed to harm and number of excess fractures in different populations of women with type 2 diabetes mellitus taking thiazolidinediones

Population	Baseline risk of fractures per 1000 patient-years	Odds ratio of fracture (95% CI) from meta-analysis	1-year number needed to harm* (95% CI)	Excess fractures with thiazolidinedione use per 1000 patient-years (95% CI)
Women in the metformin arm of the ADOPT study; mean age 56 years; diabetes diagnosed within 3 years before study; no previous use of oral hypoglycemic agent <sup>24</sup>	15.4	2.23 (1.65–3.01)	55 (34–103)	18 (10–29)
Elderly postmenopausal women in Women's Health Initiative Observational Study; mean age 65 years <sup>10</sup>	28.6	2.23 (1.65–3.01)	31 (19–57)	32 (18–53)
Older cohort of women with diabetes not using insulin; mean age 72 years <sup>40</sup>	43.5	2.23 (1.65–3.01)	21 (14–39)	48 (26–71)

Note: ADOPT = A Diabetes Outcome and Progression Trial.

\*Number of patients with type 2 diabetes who must be treated with a thiazolidinedione, rather than another intervention, for 1 additional patient to have a fracture.

statistical significance of the effect, they may alter the precision of the risk and the confidence intervals. However, not all of the currently unavailable data are negative. An independent interim analysis of fractures in a large long-term rosiglitazone trial that is underway has yielded similar results to those of the ADOPT study.<sup>7</sup>

The only available data from randomized controlled trials on reduced bone mineral density were from healthy women<sup>35</sup> and participants with polycystic ovary syndrome,<sup>36</sup> rather than patients with type 2 diabetes. However, women with diabetes are likely at similar risk, as shown in the observational studies.<sup>38</sup>

## Conclusion

Despite their limitations, our findings have potential regulatory and clinical implications. Only limited evidence exists that thiazolidinedione-induced glycemic control leads to any reduction in the complications of diabetes.<sup>58,59</sup> The relatively modest benefits of thiazolidinediones must be balanced against their significant long-term effects on bone and the cardiovascular system. Clinicians should reconsider the use of thiazolidinediones in women with type 2 diabetes. This is in accordance with the updated guidelines of the United Kingdom National Institute of Clinical Excellence.<sup>60</sup> The guidelines state: "Do not commence or continue a thiazolidinedione in people who have evidence of heart failure, or who are at higher risk of fracture." Regulatory agencies should restrict the use of thiazolidinediones in women with diabetes who are at risk for fractures.

This article has been peer reviewed.

**Competing interests:** Curt Furberg is a senior investigator and steering committee chair of the National Health, Lung, and Blood Institute-sponsored Cardiovascular Health Study (CHS), a cohort study to examine risk factors of coronary artery disease and stroke in elderly people. In 2004, the study received a grant for \$280 000 from GlaxoSmithKline to determine the relations between LpPLA-2 and various vascular diseases. The grant was primarily for the CHS central laboratory and the CHS coordinating centre. Funding was channelled through Wake Forest University, and Dr. Furberg was the CHS principal investigator. He received no salary support and the funding period ended June 30, 2006. Dr. Furberg has no funding from any other manufacturers of antidiabetic medications. Yoon Loke and Sonal Singh have no competing interests to declare.

**Contributors:** Yoon Loke and Sonal Singh conceptualized the review, developed the protocol, abstracted and analyzed the data and wrote the manuscript. Curt Furberg reviewed the draft, interpreted the data and provided critical input. Yoon Loke will act as the guarantor for the paper. All of the authors approved the final version of the manuscript submitted for publication.

**Funding:** No external funding was received for this research.

## REFERENCES

- Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. *JAMA* 2007;298:1189-95.
- Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. *Diabetes Care* 2007;30:2148-53.
- Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA* 2007;298:1180-8.
- Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007;370:1129-36.
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007;356:2457-71.
- Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum in *N Engl J Med* 2007; 356:1387-8]. *N Engl J Med* 2006;355:2427-43.
- Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia® (rosiglitazone maleate) tablets for type 2 diabetes mellitus [Dear Health Care Provider letter]. Philadelphia (PA): GlaxoSmithKline; 2007. Available: [www.fda.gov/medwatch/safety/2007/Avandia\\_GSK\\_Ltr.pdf](http://www.fda.gov/medwatch/safety/2007/Avandia_GSK_Ltr.pdf) (accessed 2008 Jul 13).
- Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus [Dear Health Care Provider letter]. Deerfield (IL): Takeda Pharmaceuticals North America; 2007. Available: [www.fda.gov/MEDWATCH/SAFETY/2007/Actosmar0807.pdf](http://www.fda.gov/MEDWATCH/SAFETY/2007/Actosmar0807.pdf) (accessed 2008 Jul 13).
- Increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus. Toronto (ON): Eli Lilly Canada Inc.; 2007. Available: [www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/actos\\_hpc-cps\\_2\\_e.html](http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2007/actos_hpc-cps_2_e.html) (accessed 2008 Jul 13).
- Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. *J Clin Endocrinol Metab* 2006;91:3404-10.
- Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. *Am J Epidemiol* 2007;166:495-505.
- GlaxoSmithKline clinical trial register. Brentford (UK): GlaxoSmithKline; 2008. Available: <http://ctr.gsk.co.uk/welcome.asp> (accessed 2008 Sept 10).
- Clinical study report summaries. Osaka (Japan): Takeda Pharmaceuticals Company Limited; 2008. Available: [www.takeda.com/c-t/report-summaries/article\\_53.html](http://www.takeda.com/c-t/report-summaries/article_53.html) (accessed 2008 Jul 13).
- Clinical Study Results database. Available: [www.clinicalstudyresults.org](http://www.clinicalstudyresults.org) (accessed 2008 Jul 13).
- Loke YK, Price D, Herxheimer A. Adverse effects. In: Higgins JPT, Green S, editors. *Cochrane handbook for systematic reviews of interventions version 5.0.0* [updated February 2008]. Chichester (UK): The Cochrane Collaboration; 2008. Available: [www.cochrane-handbook.org](http://www.cochrane-handbook.org) (accessed 2008 Sept 11).
- Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. *Stat Med* 2007;26:53-77.
- Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
- Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. *BMJ* 2007;335:914-6.
- Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. *Evolution* 2005;59:464-8.
- Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. *BMC Med Res Methodol* 2002;2:1.
- Schünemann HJ, Oxman AD, Vist GE, et al. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors. *Cochrane handbook for systematic reviews of interventions version 5.0.0* [updated February 2008]. Chichester (UK): The Cochrane Collaboration; 2008. Available: [www.cochrane-handbook.org](http://www.cochrane-handbook.org) (accessed 2008 Sept 11).
- Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading. *BMJ* 1999;318:1548-51.
- Kahn SE, Zinman B, Lachin JM, et al.; ADOPT Study Group. Rosiglitazone Associated fractures in type 2 diabetes: an analysis from ADOPT. *Diabetes Care* 2008; 31:845-51.
- Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. *Lancet* 2005;366:1279-89.
- Actos prescribing information. Deerfield (Illinois): Takeda Pharmaceuticals America Inc.; 2007. Available: [www.actos.com/actos/prescribinginfo.aspx](http://www.actos.com/actos/prescribinginfo.aspx) (accessed 2008 Jul 13).
- A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52 weeks' administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin [study no AVMI00264]. Brentford (UK): GlaxoSmithKline; 2008. Available: <http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp> (accessed 2008 Jul 13).
- RAS Rosiglitazone and Atherosclerosis Study: a 1 year randomised, double-blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome and/or type 2 diabetes mellitus [study no 049653/334]. Brentford (UK): GlaxoSmithKline; 2008. Available: <http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp> (accessed 2008 Jul 13).
- Rosiglitazone and Plaque Study: a 12 month randomised, double-blind, placebo-controlled, magnetic resonance imaging study to evaluate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes mellitus and coexisting vascular disease or hypertension [study no 049653/351]. Brentford (UK): GlaxoSmithKline; 2008. Available: <http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp> (accessed 2008 Jul 13).
- Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus study no 049653/351. *Pharmacotherapy* 2006;26:1388-95.
- Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in pa-

- tients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA* 2008;299:1561-73.
31. DeFronzo RA. Actos Now for Prevention of Diabetes (ACT NOW). NCT00220961. *Proceedings of the American Diabetes Association 68th Scientific Sessions: Late Breaking Clinical Studies*. 2008 Jun 6-10; San Francisco. Alexandria (VA) : The American Diabetes Association; 2008.
  32. Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;79:453-60.
  33. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. *Arch Intern Med* 2008;168:820-5.
  34. Fracture diagnoses in patients receiving monotherapy with antidiabetic agents, including hand and foot fractures [study no WEURTP2181]. Brentford (UK): GlaxoSmithKline; 2008. Available: <http://ctr.gsk.co.uk/Summary/rosiglitazone/studylist.asp> (accessed 2008 Jul 13).
  35. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor- $\gamma$  agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. *J Clin Endocrinol Metab* 2007;92:1305-10.
  36. Glinborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. *J Clin Endocrinol Metab* 2008;93:1696-701.
  37. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. *Diabetes Care* 2007;30:1574-6.
  38. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. *J Clin Endocrinol Metab* 2006;91:3349-5.
  39. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. *BMJ* 1995;310:452-4.
  40. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fractures. A prospective study. *J Clin Endocrinol Metab* 2001;86:32-8.
  41. Berberoglu Z, GURSOY A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. *J Clin Endocrinol Metab* 2007;92:3523-30.
  42. Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. *Endocrinology* 2005;146:1226-35.
  43. Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. *Endocrinology* 2004;145:401-6.
  44. Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. *J Endocrinol* 2004;183:203-16.
  45. Wan Y, Chong LW, Evans RM. PPAR- $\gamma$  regulates osteoclastogenesis in mice. *Nat Med* 2007;13:1496-503.
  46. Dagdelen S, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. *Adv Ther* 2007;24:1314-20.
  47. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPAR agonist BRL49653 (rosiglitazone). *Calcif Tissue Int* 2004;75:329-37.
  48. Schwartz AV, Cummings SR. Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women? *Nat Clin Pract Endocrinol Metab* 2007;3:622-3.
  49. Sanders KM, Seeman E, Ugoni AM, et al. Age- and gender-specific rate of fractures in Australia: a population-based study. *Osteoporos Int* 1999;10:240-7.
  50. Worthy K, Feight A. One year post-pediatric exclusivity post-marketing adverse event review: drug use data Avandia (rosiglitazone) tablet: NDA 21-071PID # 040849 [memorandum]. Rockville (MD): Department of Health and Human Services, US Food and Drug Administration, Public Health Service, Center for Drug Evaluation and Research; 2006. Available: [www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b\\_05\\_02\\_RosiglitazoneUseData%20Cleared.pdf](http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_05_02_RosiglitazoneUseData%20Cleared.pdf) (accessed 2008 Jul 13).
  51. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. *Diabetes Care* 2008;31:199-203.
  52. Forsen L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. *Diabetologia* 1999;42:920-5.
  53. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. *Diabetes Care* 2001;24:1192-7.
  54. Loke YK, Price D, Derry S, et al. Case reports of suspected adverse drug reactions — systematic literature survey of follow-up. *BMJ* 2006;332:335-9.
  55. US Food and Drug Administration. Adverse event reporting system. Rockville (MD): The Administration; 2008. Available: [www.fda.gov/cder/aers/default.htm](http://www.fda.gov/cder/aers/default.htm) (accessed 2008 Jul 13).
  56. Canadian Adverse Drug Reaction Monitoring Program (CADRMP) adverse reaction database. Ottawa (ON): Health Canada; 2006. Available: [www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php](http://www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php) (accessed 2008 Jul 13).
  57. Quesada-Gomez JM, Serrano-Alferez I. Nonhypoglycemic effects of thiazolidinediones. *Ann Intern Med* 2001;135:1007-8.
  58. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2006;4:CD006060.
  59. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus [review]. *Cochrane Database Syst Rev* 2007;3:CD006063.
  60. National Institute for Health and Clinical Excellence. GC66 diabetes — type 2 update: NICE guidelines. London (UK): The Institute; 2008. Available: [www.nice.org.uk/Guidance/CG66/NiceGuidance/pdf/English](http://www.nice.org.uk/Guidance/CG66/NiceGuidance/pdf/English) (accessed 2008 Jul 13).

**Correspondence to:** Dr. Yoon K. Loke, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK NR4 7TJ; fax 44 1603 593752 y.loke@uea.ac.uk



**GET TOUGH  
WITH  
CHOLESTEROL.**

Product Monograph  
available at [www.crestor.ca](http://www.crestor.ca)

For prescribing information see page 100